|
INSIDE Avian influenza situation in Asia, as of January 2005 Improving the capacity of veterinary services FAO mission to follow up outbreaks of peste des petits ruminants (PPR) Update on Haemorrhagic septicaemia and progress in vaccine research TADinfo training workshop in Windhoek, Namibia In brief...
|
Rift Valley fever surveillance in West Africa in 2004
Peste des petits ruminants in the Thrace region of Turkey
Haemorrhagic septicaemia: progress in vaccine research
AND...Update on the avian influenza situation in Asia FAO Animal Production and Health Division |
Download PDF version
Four years after the close of an FAO regional Technical Cooperation Programme project designed to improve the capacity of national veterinary services, the surveillance of RVF is still operational in the region. Activities were strengthened in 2004 in the Gambia, Mali, Mauritania and Senegal. These countries participated actively in the RVF surveillance programme by monitoring sentinel herds and searching for the disease in high-risk areas. These activities were financially supported by FAO in Mali, Mauritania and Senegal through letters of agreement with national veterinary laboratories. 
In October 2004, the General Directorate of Protection and Control of the Ministry of Agriculture and Rural Affairs of Turkey reported to the World Organisation for Animal Health that six outbreaks of PPR had occurred in September, including two outbreaks in the Edirne province. This was the first time that PPR had been reported in the Thrace region of Turkey.
Haemorrhagic septicaemia (HS) is an acute septicaemia disease of cattle and buffaloes caused by specific serotypes of the bacterium Pasteurella multocida. It is endemic in parts of Africa and Asia. The acute nature of most cases limits the efficacy of antimicrobial therapy, and vaccination appears to be an alternative effective control option. Some Asian countries have achieved success in the control of the disease by the use of alum-precipitated or oil-adjuvant vaccines. HS vaccine research concentrating on the selection of an appropriate adjuvant, ease of field application of vaccine, and cross protection against other serotypes of P. multocida, is ongoing.